Italy · Delayed Price · Currency is EUR Farmacosmo Statistics
Total Valuation
Farmacosmo has a market cap or net worth of EUR 15.83 million. The enterprise value is 22.28 million.
| Market Cap | 15.83M |
| Enterprise Value | 22.28M |
Important Dates
The next estimated earnings date is Friday, June 26, 2026.
| Earnings Date | Jun 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Farmacosmo has 38.81 million shares outstanding.
| Current Share Class | 34.72M |
| Shares Outstanding | 38.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 4.10% |
| Float | 31.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| PB Ratio | 2.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 29.84 |
| P/OCF Ratio | 28.58 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 41.99 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 1.43.
| Current Ratio | 0.78 |
| Quick Ratio | 0.50 |
| Debt / Equity | 1.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | 14.24 |
| Interest Coverage | -4.55 |
Financial Efficiency
Return on equity (ROE) is -57.09% and return on invested capital (ROIC) is -54.23%.
| Return on Equity (ROE) | -57.09% |
| Return on Assets (ROA) | -12.04% |
| Return on Invested Capital (ROIC) | -54.23% |
| Return on Capital Employed (ROCE) | -70.76% |
| Weighted Average Cost of Capital (WACC) | 8.64% |
| Revenue Per Employee | 645,225 |
| Profits Per Employee | -50,937 |
| Employee Count | 96 |
| Asset Turnover | 1.90 |
| Inventory Turnover | 8.29 |
Taxes
In the past 12 months, Farmacosmo has paid 1.06 million in taxes.
| Income Tax | 1.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.97% in the last 52 weeks. The beta is 0.42, so Farmacosmo's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -20.97% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.48 |
| Relative Strength Index (RSI) | 67.66 |
| Average Volume (20 Days) | 42,115 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Farmacosmo had revenue of EUR 56.13 million and -4.43 million in losses. Loss per share was -0.11.
| Revenue | 56.13M |
| Gross Profit | -2.42M |
| Operating Income | -5.68M |
| Pretax Income | -3.54M |
| Net Income | -4.43M |
| EBITDA | -4.21M |
| EBIT | -5.68M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 946,827 in cash and 7.55 million in debt, with a net cash position of -6.61 million or -0.17 per share.
| Cash & Cash Equivalents | 946,827 |
| Total Debt | 7.55M |
| Net Cash | -6.61M |
| Net Cash Per Share | -0.17 |
| Equity (Book Value) | 5.29M |
| Book Value Per Share | 0.14 |
| Working Capital | -4.37M |
Cash Flow
In the last 12 months, operating cash flow was 554,147 and capital expenditures -23,487, giving a free cash flow of 530,660.
| Operating Cash Flow | 554,147 |
| Capital Expenditures | -23,487 |
| Depreciation & Amortization | 2.65M |
| Net Borrowing | -27,038 |
| Free Cash Flow | 530,660 |
| FCF Per Share | 0.01 |
Margins
Gross margin is -4.32%, with operating and profit margins of -10.12% and -7.89%.
| Gross Margin | -4.32% |
| Operating Margin | -10.12% |
| Pretax Margin | -6.31% |
| Profit Margin | -7.89% |
| EBITDA Margin | -7.50% |
| EBIT Margin | -10.12% |
| FCF Margin | 0.95% |
Dividends & Yields
Farmacosmo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -27.99% |
| FCF Yield | 3.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Farmacosmo has an Altman Z-Score of 1.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.15 |
| Piotroski F-Score | 4 |